secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-076768
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Q4 revenue $62.1M (+8% YoY); net loss $44.1M on $38.1M deferred tax valuation allowance
--------------------------------------------------------------------------------

- Full-year 2025 revenue $201.5M (+1% YoY); Q4 set record quarterly revenue.
- GAAP gross margin 53% in Q4 vs 59% a year ago; adjusted gross margin 55% vs 61%.
- Full-year net loss $66.5M vs $6.0M in 2024, driven by $33.1M non-cash deferred tax valuation allowance and higher expenses.
- Adjusted EBITDA for 2025 was $5.0M, down from $22.4M; excluding investment income, was $(3.1)M.
- Guides FY2026 revenue of $205-212M, representing 2-5% growth over 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312526076768/0001193125-26-076768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312526076768/d106442d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-076768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer